Fig. 1. Proposed changes to treatment algorithms for advanced cervical cancer after 2023.

Changes are necessitated by the introduction of new treatment options in first line (atezolizumab) and late-line (trastuzumab deruxtecan). Furthermore, results of the confirmatory phase III trial for second- to third-line tisotumab vedotin versus chemotherapy were announced in 2023.

CPS, combined positive score; HER2, human epidermal growth factor 2; ICI, immune checkpoint inhibitor; IHC, immunohistochemistry; PD-L1, programmed death-ligand 1.